Sign up to save your podcasts
Or
Share 30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 1 FDA Drug Development Overview
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 1 FDA Drug Development Overview
This podcast episode provides a comprehensive overview of the FDA drug development process for cannabinoid and psychedelic therapeutics. The hosts discuss the journey from pre-clinical research through post-marketing surveillance, explaining key stages including:
- Pre-clinical research and molecular interactions with brain receptors
- The IND (Investigational New Drug) application process
- The three phases of clinical trials and their purposes
- Special challenges related to Schedule I substances and regulatory hurdles
The conversation also explores broader implications for mental health treatment and addiction, emphasizing how these emerging therapies could reshape our understanding of healing and consciousness.
View all episodes
By Jim Mitchell and Google NotebookLMThis podcast episode provides a comprehensive overview of the FDA drug development process for cannabinoid and psychedelic therapeutics. The hosts discuss the journey from pre-clinical research through post-marketing surveillance, explaining key stages including:
- Pre-clinical research and molecular interactions with brain receptors
- The IND (Investigational New Drug) application process
- The three phases of clinical trials and their purposes
- Special challenges related to Schedule I substances and regulatory hurdles
The conversation also explores broader implications for mental health treatment and addiction, emphasizing how these emerging therapies could reshape our understanding of healing and consciousness.